leadf
logo-loader
viewIncanthera Ltd

Incanthera completes £350,000 fundraising, with ImmuPharma increasing stake

“ImmuPharma is a strong supporter of Incanthera,” said chief executive Dimitri Dimitriou

ImmuPharma PLC -

ImmuPharma PLC (LON:IMM) has increased its stake in Incanthera PLC (AQSE:INC) as the developer of an innovative sun cream raised £350,000 in a share subscription.

As part of an agreement entered into at the time of Incanthera’s flotation on the AQSE Growth Market in February, ImmuPharma has increased its stake to 15.35% as it subscribed for £250,000 of shares at the float price of 9.5p apiece.

Tim McCarthy, chairman of both companies, and several other directors and other employees of Incanthera subscribed for the remaining £100,000 at the same price.

McCarthy now has a 6.01% stake, while chief executive Simon Ward upped his stake to 4.11%.

Ward said: “Incanthera welcomes the completion of the subscription agreement by ImmuPharma and acknowledges their continued support and belief of the potential within our company and our pipeline.

“Similarly, I welcome the commitment of my fellow directors and management for their decisions to subscribe alongside our chairman, for additional shares, which underlines their dedication to the future success of the company for the benefit of both patients and shareholders.”

Dimitri Dimitriou, ImmuPharma's chief executive officer, added: “ImmuPharma is a strong supporter of Incanthera, sharing common goals of progressing both of our therapeutic pipelines to benefit the long term health of patients, globally.

“We are extremely pleased to note Incanthera's two recent announcements, evidencing great progress towards its immediate goal of taking its lead product Sol to market.”

Incanthera’s lead product is Sol, a potentially innovative topical product for the treatment of solar keratosis and the prevention of skin cancers, which has achieved proof of concept and is currently being prepared for licensing to a commercial partner.

Quick facts: Incanthera Ltd

Price: 17 GBX

AQSE:INC
Market: AQSE
Market Cap: -
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Incanthera Ltd named herein, including the promotion by the Company of Incanthera Ltd in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Incanthera believe new skin cancer prevention cream reveals 'all positives...

Incanthera PLC's (AQSE:INC) CEO Simon Ward and Kevin Hammond talk to Proactive London's Katie Pilbeam about new positive data from new skin permeation and sensitisation studies of its Sol skin cancer technology. Both Simon and Kevin explain that Sol is a cream designed to deliver an active...

2 weeks ago

2 min read